UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 16 Source: CRO
- €167.1 million turnover
-
-€10.4 million
profit - 44 employees
-
31st Dec 15 Source: CRO
- €136.4 million turnover
-
€461.9 million
profit - 120 employees
- 8 more years available »
Ranking
By Turnover
(€167.1 million)- 340th in Top Companies
- 39th in Health
- 40th in Pharma
By Employees
(44)- 870th in Top Companies
- 97th in Health
- 82nd in Pharma
-
- 44
- €167.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 8:15am Former Quinn firm sues Fermanagh farmer over material posted online
- 7:46am Balark petition to appoint statutory liquidator to Chambury rejected
- 7:00am US investment firms poised to sell Cherrywood land to builders
- 1:00am News publishers highlight importance of journalism in Irish democracy
- Sep 21 From riches to rags: Norwegian trader’s €114m bet backfires